Targets
receptor tyrosine kinases (RTKs)
- ERBB1 (ErbB: HER1/EGF):
-
ERBB2 (HER2/neu)
- trastuzumab
- apatinib, neratinib
- C-kit (KIT)
- Axitinib, Sunitinib, Sorafenib
- FLT3: lestaurtinib
- PDGFR: axitinib, sunitinib, sorafenib
- VEGFR: vandetanib, semaxanib, cediranib, axitinib, sunitinib, sorafenib
EpCAM: catumaxomab, edrecolomab
VEGF-A (VEGFA)
- bevacizumab (Avastil)
- fusion protein against VEGF: aflibercept
CD20: rituximab, tositumomab, ibritumomab
CD52: alemtuzumab
CD33: gemtuzumab
BCR-ABL fusion protein : imatinib, nilotinib, dasatinib
ABL1
SRC (Src): bosutinib
EGFR
Janus kinase 2 (JAK2): lestaurtinib
IL-2
- exotoxin against IL-2 (denileukin diftitox)
References
Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006 Sep;6(9):714-27. PMID: 16929325
Hannah AL. Kinases as drug discovery targets in hematologic malignancies. Curr Mol Med. 2005 Nov;5(7):625-42. PMID: 16305489
Savage DG, Antman KH. Imatinib mesylate—a new oral targeted therapy. N Engl J Med. 2002 Feb 28;346(9):683-93. PMID: 11870247